[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 462
1. Sheu SY, Handke S, Bröcker-Preuss M, Görges R, Frey UH, Ensinger C, Ofner D, Farid NR, Siffert W, Schmid KW: The C allele of the GNB3 C825T polymorphism of the G protein beta3-subunit is associated with an increased risk for the development of oncocytic thyroid tumours. J Pathol; 2007 Jan;211(1):60-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carriers of the C allele of the common C825T polymorphism in the GNB3 gene of the G protein have been associated with the development of follicular thyroid adenomas.
  • Using pyrosequencing, both the genotype distribution and the allele frequency of the C825T polymorphism were investigated in a series of 104 patients with oncocytic thyroid tumours of follicular cell origin [58 adenomas, 41 follicular thyroid carcinomas (FTCs), and five papillary thyroid carcinomas (PTCs)]; the results were compared with those obtained from 321 age and gender-matched healthy blood donors and a series of 327 non-oncocytic thyroid tumours of follicular cell origin (119 adenomas, 80 FTCs, and 186 PTCs).
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Heterotrimeric GTP-Binding Proteins / genetics. Polymorphism, Genetic. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Alleles. Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. Case-Control Studies. Female. Gene Frequency. Genotype. Humans. Male. Middle Aged. Mitochondria / metabolism. Odds Ratio. Risk. Thyroid Hormones / biosynthesis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 17136758.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / G-protein beta3 subunit; 0 / Thyroid Hormones; EC 3.6.5.1 / Heterotrimeric GTP-Binding Proteins
  •  go-up   go-down


2. Arnaldi LA, Borra RC, Maciel RM, Cerutti JM: Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid; 2005 Mar;15(3):210-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DCN was found underexpressed in a high percentage of the follicular thyroid adenomas, follicular thyroid carcinomas, and follicular variant of papillary thyroid carcinomas.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Primers. Decorin. Extracellular Matrix Proteins. Female. Humans. Isoenzymes / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Open Reading Frames. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785240.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DCN protein, human; 0 / DNA Primers; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Isoenzymes; 0 / Proteoglycans; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


3. Naoi Y, Miyoshi Y, Taguchi T, Kim SJ, Arai T, Maruyama N, Tamaki Y, Noguchi S: Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers. Cancer Lett; 2008 Apr 18;262(2):248-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers.
  • In the study presented here, we investigated Cx26 expression in human papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) and its relationship with various clinicopathological parameters.
  • Of 69 PTCs, 33 were positive for Cx26 (47.8%), as were five of 11 FTCs (45.5%), all follicular thyroid adenomas (n=22) and normal thyroid tissues (n=20) were negative for Cx26.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary / genetics. Connexins / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18191019.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


Advertisement
4. Hoftijzer HC, Liu YY, Morreau H, van Wezel T, Pereira AM, Corssmit EP, Romijn JA, Smit JW: Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. Eur J Endocrinol; 2009 Apr;160(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We used a tissue array containing 93 benign thyroid tissues (normal thyroid, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155317.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors
  •  go-up   go-down


5. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R: Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest; 2009 Jul;89(7):791-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously demonstrated that most differentiated thyroid neoplasms, including follicular adenomas/carcinomas and papillary carcinomas, express TTF-1 at both protein and mRNA levels.
  • We evaluated the expression of TTF-1 in primary thyroid tissues (normal thyroid, papillary carcinoma and undifferentiated carcinoma) and in thyroid carcinoma cell lines using immunohistochemistry and RT-PCR.
  • In our current study, immunohistochemistry and RT-PCR showed positive expression of TTF-1 in normal thyroids and papillary carcinomas.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506552.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Histones; 0 / Hydroxamic Acids; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


6. Hester SD, Nesnow S: Transcriptional responses in thyroid tissues from rats treated with a tumorigenic and a non-tumorigenic triazole conazole fungicide. Toxicol Appl Pharmacol; 2008 Mar 15;227(3):357-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conazoles can induce follicular cell adenomas of the thyroid in rats after chronic bioassay.


7. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch; 2005 Jun;446(6):589-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another BRAF mutation (K601E) was detected in a follicular adenoma and in some cases of the follicular variant of PTC.
  • The BRAF(V600E) mutation was exclusively detected in PTC with a papillary or mixed follicular/papillary architecture both of the conventional type (46%) and of other histotypes, such as microcarcinoma (43%), Warthin-like PTC (75%) and oncocytic variant of PTC (55%).
  • The BRAF(K601E) mutation was detected in four of the 54 cases of the follicular variant of PTC (7%).
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Age Factors. Carcinoma, Papillary, Follicular / genetics. DNA Mutational Analysis. Humans. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Sex Factors

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2002 Winter;13(4):289-99 [12665647.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Yonsei Med J. 2004 Oct 31;45(5):818-21 [15515191.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):287-94 [9516913.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Cancer Lett. 2004 Jun 8;209(1):1-6 [15145515.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):90-100 [3843693.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2414-20 [15126572.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] J Pathol. 1998 May;185(1):71-8 [9713362.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):313-20 [12665649.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):237-40 [11886336.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 [12970315.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 [15356020.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):342-8 [15009715.001]
  • (PMID = 15902486.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


8. Yamanaka K, Ito Y, Okuyama N, Noda K, Matsumoto H, Yoshida H, Miyauchi A, Capurro M, Filmus J, Miyoshi E: Immunohistochemical study of glypican 3 in thyroid cancer. Oncology; 2007;73(5-6):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GPC3 was scarcely expressed in the normal thyroid gland, but was dramatically enhanced in certain types of cancers: 100% in follicular carcinoma (20/20 cases) and 70% in papillary carcinoma (48/69 cases).
  • Expression of GPC3 in follicular carcinoma was significantly higher than that of follicular adenoma (p < 0.0019).
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Carcinoma / genetics. Carcinoma / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Gene Amplification. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Staging. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18511877.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / GPC3 protein, human; 0 / Glypicans
  •  go-up   go-down


9. Magro G, Benkova K, Michal M: Meningioma-like tumor of the thyroid: a previously undescribed variant of follicular adenoma. Virchows Arch; 2005 Jun;446(6):677-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma-like tumor of the thyroid: a previously undescribed variant of follicular adenoma.
  • [MeSH-major] Adenoma / pathology. Meningioma / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] AMA Arch Pathol. 1954 Dec;58(6):554-63 [13217570.001]
  • [Cites] Endocr Pract. 2001 Sep-Oct;7(5):370-4 [11585373.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):91-2 [15517364.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):199-204 [11863215.001]
  • (PMID = 15891903.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Eszlinger M, Paschke R: Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol; 2010 Jun 30;322(1-2):29-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While approximately 75% of FNAB reveal benign lesions and 5% already cytologically prove malignancy, up to 20% of FNAB show follicular proliferation for which follicular adenoma, follicular carcinoma, and follicular variant of papillary carcinoma can only be distinguished histologically, thus requiring thyroid surgery.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis. Thyroid Nodule / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20083161.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 123
  •  go-up   go-down


11. Mofid AR, Yazdani T, Shahrzad M, Seyedalinaghi S, Zandieh S: Role of fine-needle aspiration in the management of thyroid nodules. Saudi Med J; 2009 Apr;30(4):515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The cytology diagnoses by FNAB were: papillary 6 (3.2%); follicular neoplasm 51 (28%); follicular adenoma 10 (5.4%); Hurthle cell neoplasm 8 (4.3%); suspicious 20 (10.9%); inconclusive 2 (1%); and benign 85 (46.4%).
  • Due to surgery pathologic reports, malignant cytologies were: 6 (100%) for papillary, 1 (1.96%) for follicular neoplasm, 4 (50%) for Hurthle cell neoplasm.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370278.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


12. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV: Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol; 2006;17(3):213-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
  • These analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p < 0.0001).
  • A combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma.
  • These results indicate that some individual antibodies or a panel of antibodies combined with histopathological analysis can be useful in separating follicular adenoma (FA) from follicular variant of papillary thyroid carcinoma (FVPTC).
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):319-27 [15681856.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Eur J Cancer Clin Oncol. 1986 Dec;22(12):1441-52 [2439341.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] Pathol Res Pract. 1997;193(10):705-12 [9505263.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):654-8 [2479256.001]
  • [Cites] Endocr Pathol. 2003 Spring;14 (1):37-48 [12746561.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1065-75 [15980887.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1277-84 [16265347.001]
  • [Cites] Oncology. 2004;67(5-6):397-402 [15713996.001]
  • [Cites] Surgery. 1994 Dec;116(6):1031-5 [7985083.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Thyroid. 2004 Nov;14(11):881-8 [15671765.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6146-54 [15579771.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):53-60 [16760580.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3036-41 [1710535.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1374-80 [12481020.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Thyroid. 2004 Mar;14(3):169-75 [15072698.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):301-11 [12665648.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):175-83 [11786411.001]
  • [Cites] Hum Pathol. 1995 Feb;26(2):139-46 [7860043.001]
  • (PMID = 17308358.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Cardenas MG, Kini S, Wisgerhof M: Two patients with highly aggressive macrofollicular variant of papillary thyroid carcinoma. Thyroid; 2009 Apr;19(4):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The macrofollicular variant of papillary thyroid carcinoma (MFV-PTC) is an unusual type of thyroid carcinoma with histological features that can be confused with nodular goiter or follicular adenoma.
  • SUMMARY: The first patient was a 59-year-old woman with an occipital mass diagnosed histologically as papillary thyroid carcinoma (PTC), follicular variant.
  • Three years later he developed a right shoulder mass, histologically diagnosed as follicular variant of PTC.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19355832.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Fadare O, Parkash V, Fiedler PN, Mayerson AB, Asiyanbola B: Tumor-to-tumor metastasis to a thyroid follicular adenoma as the initial presentation of a colonic adenocarcinoma. Pathol Int; 2005 Sep;55(9):574-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis to a thyroid follicular adenoma as the initial presentation of a colonic adenocarcinoma.
  • Herein is described the case of a 59-year-old woman whose thyroid nodule (a follicular adenoma) was resected and found to contain foci of a well-differentiated adenocarcinoma with a morphologic and immunohistochemical profile consistent with origination from the lower gastrointestinal tract.
  • In general, strikingly divergent morphologic features in an otherwise typical thyroid neoplasm should elicit a differential diagnosis that takes into consideration the possibility of metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Colonic Neoplasms / pathology. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for follicular adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143033.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 23
  •  go-up   go-down


15. Lee S, Hong SW, Moon WC, Oh MR, Lee JK, Ahn CW, Cha BS, Kim KR, Lee HC, Lim SK: High prevalence of c-RET expression in papillary thyroid carcinomas from the Korean population. Thyroid; 2005 Mar;15(3):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Thirty-six papillary thyroid carcinomas (PTCs), 8 follicular thyroid carcinomas (FTCs), 4 anaplastic thyroid carcinomas (ATC), 7 follicular adenomas (FAs), 23 hyperplasias, 6 normal thyroid tissues, and 39 normal portions from each tumor were included in this study.
  • Reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemical analyses were used to identify the RET gene and RET/PTC rearrangements.
  • RESULTS: From the RT-PCR analysis, 68.9% of the PTCs, a single case of FTC, and 22.2% of the hyperplasias expressed the RET gene.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785245.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


16. Ruschenburg I, Vollheim B, Stachura J, Cordon-Cardo C, Korabiowska M: Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. Anticancer Res; 2006 May-Jun;26(3A):2107-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the expression and mutations of MLH1, MSH2, PMS1 and PMS2 in a panel of thyroid tumours, including nodular hyperplasia, follicular adenomas and carcinomas, were investigated.
  • This observation can find potential diagnostic application in the differentiation of follicular adenomas from follicullar carcinomas of the thyroid.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adenosine Triphosphatases / biosynthesis. Adenosine Triphosphatases / genetics. Adolescent. Adult. Aged. Base Sequence. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carrier Proteins / biosynthesis. Carrier Proteins / genetics. DNA Repair Enzymes / biosynthesis. DNA Repair Enzymes / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Female. Gene Expression. Humans. Hyperplasia. Male. Middle Aged. Molecular Sequence Data. MutS Homolog 2 Protein / biosynthesis. MutS Homolog 2 Protein / genetics. Neoplasm Invasiveness. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Nuclear Proteins / biosynthesis. Nuclear Proteins / genetics. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827152.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / PMS1 protein, human; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


17. Mattioli F, Martelli A, Garbero C, Gosmar M, Manfredi V, Mattioli FP, Torre G, Brambilla G: DNA fragmentation and DNA repair synthesis induced in rat and human thyroid cells by four rat thyroid carcinogens. Toxicol Appl Pharmacol; 2005 Mar 1;203(2):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four chemicals that are known to induce in rats thyroid follicular-cell adenomas and carcinomas were assayed for their ability to induce DNA damage and DNA repair synthesis in primary cultures of human thyroid cells.

  • Hazardous Substances Data Bank. BIS(P-(DIMETHYLAMINO)PHENYL)METHANE .
  • Hazardous Substances Data Bank. 4,4'-THIOBISBENZENAMINE .
  • Hazardous Substances Data Bank. 2,4-DIAMINOANISOLE SULFATE .
  • Hazardous Substances Data Bank. PROPYL THIOURACIL .
  • Hazardous Substances Data Bank. 2,4-DIAMINOANISOLE DIHYDROCHLORIDE .
  • Hazardous Substances Data Bank. 2,4-DIAMINOANISOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710170.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antithyroid Agents; 0 / Carcinogens; 0 / Phenylenediamines; 6GGU990BQF / 4,4'-thiodianiline; 721M9407IY / Propylthiouracil; 86SSM2N1X7 / 4-methoxy-3-phenylenediamine; L6SPP9K4WQ / N,N,N',N'-tetramethyl-4,4'-methylenedianiline
  •  go-up   go-down


18. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M: Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Hum Pathol; 2008 Nov;39(11):1656-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 193 archival thyroid samples including 28 follicular adenomas, 18 follicular carcinomas, and 147 papillary carcinomas with 114 adjacent thyroid tissues were analyzed by immunohistochemistry.
  • In patients with follicular carcinoma, the extent of invasiveness was associated with galectin-3 positivity.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657294.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


19. Kirillov V, Gladyshev A, Demidchik E: Technology of creation of an expert system for diagnosing thyroid pathology based on a set of qualitative signs of cell atypia. Microsc Res Tech; 2010 Dec;73(12):1091-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S-matrices characterized the main forms of thyroid diseases, such as papillary and follicular cancer, follicular adenoma, autoimmune thyroiditis, nodular colloid and diffuse toxic goiter, by their set of yes/no answers.

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • (PMID = 20309888.001).
  • [ISSN] 1097-0029
  • [Journal-full-title] Microscopy research and technique
  • [ISO-abbreviation] Microsc. Res. Tech.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Matesa N, Samija I, Kusić Z: Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions. Cytopathology; 2007 Apr;18(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions.
  • OBJECTIVE: To investigate whether the presence of macrophages and Hürthle cells (HC) in benign thyroid lesions could explain the false-positive expression of galectin-3 and CD44v6 detected by reverse transcriptase-polymerase chain reaction (RT-PCR).
  • METHODS: For galectin-3 and CD44v6, RT-PCR was performed on RNA isolated from aspirates obtained by ultrasound guided fine needle aspiration cytology (FNAC) from 123 patients with benign thyroid lesions.
  • The results of RT-PCR analysis were evaluated against the definitive FNAC diagnosis.
  • RESULTS: Galectin-3 expression was found in 29% follicular adenoma (FA), 26% Hashimoto thyroiditis (HT), and in 24% nodular goitre (NG).
  • CONCLUSION: Our results suggest that the presence of macrophages and/or HC may explain the positive expression of galectin-3 and CD44v6 detected by RT-PCR in HT and NG cytological samples.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. False Positive Reactions. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Hashimoto Disease / metabolism. Hashimoto Disease / pathology. Humans. Macrophages / metabolism. Macrophages / pathology. Oxyphil Cells / metabolism. Oxyphil Cells / pathology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17397496.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers; 0 / CD44v6 antigen; 0 / Galectin 3; 0 / Glycoproteins; 0 / RNA, Messenger
  •  go-up   go-down


21. Stolf BS, Santos MM, Simao DF, Diaz JP, Cristo EB, Hirata R Jr, Curado MP, Neves EJ, Kowalski LP, Carvalho AF: Class distinction between follicular adenomas and follicular carcinomas of the thyroid gland on the basis of their signature expression. Cancer; 2006 May 1;106(9):1891-900
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class distinction between follicular adenomas and follicular carcinomas of the thyroid gland on the basis of their signature expression.
  • The majority of these nodules are benign, corresponding to goiters or adenomas, and only a small fraction corresponds to carcinomas.
  • Among thyroid tumors, the diagnosis of follicular adenocarcinomas by preoperative fine-needle aspiration biopsy is a major challenge, because it requires inspection of the entire capsule to differentiate it from adenoma.
  • METHODS: Using data from gene expression analysis, the authors applied Fisher linear discriminant analysis and searched for expression signatures of individual samples of adenomas and follicular carcinomas that could be used as molecular classifiers for the precise classification of malignant and nonmalignant lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / classification. Adenoma / classification. Thyroid Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565969.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Anderson CE, Graham C, Herriot MM, Kamel HM, Salter DM: CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto's thyroiditis. Histopathology; 2009 Dec;55(6):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: One hundred and forty thyroid cases were selected from the archives of the Department of Pathology, including normal controls, neoplasms (follicular adenoma, follicular carcinoma and papillary carcinoma) and non-neoplastic conditions (multinodular goitre, Graves' disease and Hashimoto's thyroiditis).
  • In normal thyroid, there was moderately strong expression of CD98 in the lateral cell membranes of follicular cells.
  • A similar pattern of expression was seen in follicular adenoma, minimally invasive follicular carcinoma, multinodular goitre and Graves' disease.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Down-Regulation. Graves Disease / metabolism. Humans. Immunohistochemistry. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922591.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD98
  •  go-up   go-down


23. Demirag F, Cakir E, Aydin E, Kaya S, Akyurek N: Ectopic primary B cell lymphoma of the thyroid presenting as an anterior mediastinal mass. A case report. Acta Chir Belg; 2009 Nov-Dec;109(6):802-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follicular adenoma, papillary carcinoma and follicular carcinoma in the mediastinum has been reported, but primary ectopic thyroid B cell lymphoma has not been reported previously.

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184075.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


24. Aiad H, Abdou A, Bashandy M, Said A, Ezz-Elarab S, Zahran A: Computerized nuclear morphometry in the diagnosis of thyroid lesions with predominant follicular pattern. Ecancermedicalscience; 2009;3:146
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized nuclear morphometry in the diagnosis of thyroid lesions with predominant follicular pattern.
  • BACKGROUND: Differential diagnosis of thyroid lesions with predominantly follicular pattern is one of the most common problems in thyroid pathology.
  • This work is aimed at studying the role of nuclear morphometry in differential diagnosis of different thyroid lesions having predominant follicular pattern.
  • MATERIAL AND METHODS: Semiautomatic image analysis system was used to measure a total of 8 nuclear parameters in 48 thyroid lesions including seven nodular goiter (NG), 14 follicular adenoma (FA), 14 follicular carcinoma (FC) and 13 follicular variant papillary carcinoma (FVPC).
  • CONCLUSION: Nuclear morphometric parameters may help in the differentiation between neoplastic and non-neoplastic thyroid lesions and between FVPC and follicular neoplasms (FC and FA) but they have no value in the differentiation between FC and FA.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276011.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224013
  • [Keywords] NOTNLM ; Thyroid / differential diagnosis / nuclear morphometry
  •  go-up   go-down


25. Takami HE, Ikeda Y: Minimally invasive thyroidectomy. Curr Opin Oncol; 2006 Jan;18(1):43-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present indications for this procedure include benign follicular adenomas less than 4 cm in diameter, low-risk papillary carcinomas less than 10 mm, oxyphilic cell tumors less than 4 cm and Graves' disease as imaged on preoperative ultrasonography.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357563.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  • [Number-of-references] 17
  •  go-up   go-down


26. Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Friguglietti CU, Ferro MC, Kulcsar MA, Kimura ET: Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arq Bras Endocrinol Metabol; 2010 Jun;54(4):406-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although TGF-beta and activin exert antiproliferative roles in thyroid follicular cells, thyroid tumors express high levels of these proteins.
  • MATERIALS AND METHODS: The protein expression of SMADs was evaluated in multinodular goiter, follicular adenoma, papillary and follicular carcinomas by immunohistochemistry.
  • [MeSH-minor] Adenoma / metabolism. Carcinoma, Papillary, Follicular / metabolism. Goiter, Nodular / metabolism. Humans. Signal Transduction / physiology. Smad2 Protein / analysis. Smad3 Protein / analysis. Smad4 Protein / analysis. Smad7 Protein / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625653.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / SMAD4 protein, human; 0 / SMAD7 protein, human; 0 / Smad Proteins, Receptor-Regulated; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Smad4 Protein; 0 / Smad7 Protein; 0 / Transforming Growth Factor beta; 104625-48-1 / Activins
  •  go-up   go-down


27. Ito Y, Uramoto H, Funa K, Yoshida H, Jikuzono T, Asahi S, Higashiyama T, Tomoda C, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Delta Np73 expression in thyroid neoplasms originating from follicular cells. Pathology; 2006 Jun;38(3):205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delta Np73 expression in thyroid neoplasms originating from follicular cells.
  • In this study, we investigated the expression of delta Np73 in human thyroid neoplasms originating from follicular cells.
  • RESULTS: Normal follicular cells did not express delta Np73, but 27.3% of follicular adenoma, 85.4% of follicular carcinoma, 99.2% of papillary carcinoma, and 95.7% of anaplastic carcinoma were positive for the transcript.
  • Delta Np73 expression level did not differ between widely invasive and minimally invasive follicular carcinomas.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753740.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


28. Deiana L, Lai ML, Carta G, Mariotti S: Correspondence between ultrasonography and histological features in a single thyroid nodule with coexisting follicular adenoma and papillary carcinoma. Thyroid; 2008 Jul;18(7):813-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correspondence between ultrasonography and histological features in a single thyroid nodule with coexisting follicular adenoma and papillary carcinoma.
  • [MeSH-major] Adenoma / pathology. Adenoma / ultrasonography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / ultrasonography. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / pathology. Thyroid Nodule / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631017.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


29. Ito Y, Arai K, Nozawa R, Yoshida H, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Kuma K, Miyauchi A: S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res; 2007 Jul-Aug;27(4C):2679-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma.
  • RESULTS: S10A10 and annexin II were not expressed in normal follicular cells or any follicular adenomas.
  • Cells stained positively in 14.6% and 20.8% of follicular carcinomas for S100A10 and annexin II, respectively, but their expression levels were always low.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Epithelium / metabolism. Epithelium / pathology. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695432.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Annexin A2; 0 / S100 Proteins; 0 / S100 calcium binding protein A10
  •  go-up   go-down


30. Garg M, Kanojia D, Suri S, Gupta S, Gupta A, Suri A: Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab; 2009 Nov;94(11):4613-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING, AND SUBJECTS: SPAG9 gene and protein expression was determined in thyroid cancer cell lines in 138 thyroid tumor specimens, 60 adjacent noncancerous tissues (ANCT), 22 multinodular goiters (nonneoplastic hyperplasia), and 20 follicular adenoma tissue samples by RT-PCR, in situ RNA hybridization, and immunohistochemistry.
  • RESULTS: SPAG9 mRNA and protein expression was detected in 78% of the thyroid cancer patients but not multiple goiters and follicular adenoma disease patients.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820019.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / SPAG9 protein, human
  •  go-up   go-down


31. Lee B, Sir JJ, Park SW, Kim SB, Nah JC, Kang YK, Lee HK, Kim YI, Cho WH, Choi SK: Right-sided myxomas with extramedullary hematopoiesis and ossification in Carney complex. Int J Cardiol; 2008 Nov 12;130(2):e63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had previously been diagnosed as Cushing's syndrome and undergone resection of pituitary adenoma at the age of 21.
  • Thyroid ultrasonography revealed multiple hypoechoic nodules, which were confirmed pathologically as follicular adenomas.

  • Genetic Alliance. consumer health - Carney Complex.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18230408.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


32. De Nicola H, Szejnfeld J, Logullo AF, Wolosker AM, Souza LR, Chiferi V Jr: Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasms. J Ultrasound Med; 2005 Jul;24(7):897-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasms.
  • OBJECTIVES: The purpose of this study was to evaluate whether flow pattern and resistive index (RI) are useful parameters for distinguishing benign from malignant thyroid follicular neoplasms (FNs).
  • RESULTS: Ten nodules (11.63%) were malignant (3 follicular carcinomas, 5 follicular variants of papillary carcinoma, and 2 papillary carcinomas).
  • Fourteen nodules (16.27%) were adenomas, and 62 (72%) were non-neoplastic nodules.
  • The average RI in non-neoplastic nodules was 0.588 (P < .001, chi(2) test): 0.662 in adenomas and 0.763 in malignant nodules.
  • Flow patterns 1 and 2 (peripheral flow only or predominantly) were present in 58 non-neoplastic nodules (93.5%), 10 adenomas (71.4%), and 2 malignant nodules (20%).
  • Flow pattern type 3 (predominantly central flow) was present in 7 malignant nodules (70%), 4 adenomas (28.6%), and 4 non-neoplastic nodules (6.5%).
  • Resistive index values in non-neoplastic nodules were lower than in adenomas and malignant nodules (P < .001, chi(2) test).
  • [MeSH-major] Adenoma / blood supply. Adenoma / diagnosis. Carcinoma / blood supply. Carcinoma / diagnosis. Thyroid Neoplasms / blood supply. Thyroid Neoplasms / diagnosis. Vascular Resistance

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972703.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Kim KH, Kim SH, Kim SH, Back JH, Park MJ, Kim JM: Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation. J Korean Med Sci; 2006 Dec;21(6):1064-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the expressions of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in thyroid neoplasms in a Korean population, we studied a total of 154 cases: papillary carcinoma of classical type (PTC), 86; follicular adenoma (FA), 21; follicular carcinoma (FC), 35; medullary carcinoma (MC), 3; undifferentiated carcinoma (UC), 5; and Hurthle cell neoplasm (HN), 4.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Thyroid. 1999 Feb;9(2):113-7 [10090309.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G688-96 [11518681.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] Ann Clin Lab Sci. 2001 Oct;31(4):325-48 [11688844.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):358-63 [11788675.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):238-42 [11889377.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):546-51 [11939728.001]
  • [Cites] Prostate. 2002 Nov 1;53(3):232-40 [12386924.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):331-40 [12665651.001]
  • [Cites] Histopathology. 2003 May;42(5):492-7 [12713627.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1604-10 [12738712.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):434-9 [12828608.001]
  • [Cites] Korean J Intern Med. 2003 Dec;18(4):225-9 [14717230.001]
  • [Cites] Histopathology. 2004 May;44(5):490-7 [15139997.001]
  • [Cites] Br J Pharmacol. 1993 Mar;108(3):833-7 [7682140.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1352-4 [7509718.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):727-30 [7531613.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2625-34 [9169492.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] BJU Int. 2000 Oct;86(6):736-41 [11069387.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):303-8 [11196178.001]
  • [Cites] Antioxid Redox Signal. 2001 Apr;3(2):231-48 [11396478.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):S35-9 [11442675.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2445-51 [9278337.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31138-48 [9388267.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Laryngoscope. 1999 Jan;109(1):148-52 [9917057.001]
  • (PMID = 17179688.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2721930
  •  go-up   go-down


34. Granja F, Morari EC, Assumpção LV, Ward LS: GSTO polymorphism analysis in thyroid nodules suggest that GSTO1 variants do not influence the risk for malignancy. Eur J Cancer Prev; 2005 Jun;14(3):277-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to investigate the role of GSTO1 inheritance pattern on thyroid cancer risk we used a polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP)-sequencing approach to compare the genotypes of 173 (87 women, 86 men; 18-81 years old; 47+/-18 years old) healthy control individuals with those of 145 patients with thyroid nodules (84 women, 61 men; 17-81 years old; 49+/-14 years old) including 17 follicular carcinomas, 76 papillary carcinomas, 21 follicular adenomas and 31 multinodular goiters.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Polymorphism, Genetic. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901998.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.5.1.18 / GSTO1 protein, human; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


35. Sarquis MS, Weber F, Shen L, Broelsch CE, Jhiang SM, Zedenius J, Frilling A, Eng C: High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas. J Clin Endocrinol Metab; 2006 Jan;91(1):262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas.
  • DESIGN: In total, thyroid tissue was obtained from 72 patients with thyroid neoplasias comprising 34 follicular thyroid carcinomas (FTCs) and 38 follicular adenomas.
  • RESULTS: Overall LOH frequencies for the IR markers were 26% for the adenomas and 38% for the carcinomas.
  • In the NIR, the overall LOH frequency was 23 and 26% for adenomas and FTCs, respectively.
  • The difference in LOH frequencies between IR and NIR was statistically significant only for the carcinomas (P = 0.001), although there was a similar trend for the atypical adenomas (ATY, P = 0.06).
  • The fact that the ATY trended toward differential IR/NIR LOH, similar to FTC, may suggest that loss of IR might be instrumental in the adenoma-carcinoma sequence in thyroid carcinogenesis and that ATY could be an important intermediate in this pathway.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary, Follicular / genetics. Genomic Imprinting. Loss of Heterozygosity / physiology. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249278.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P30CA16058
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


36. Mai KT, Elmontaser G, Perkins DG, Thomas J, Stinson WA: Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma. Int J Surg Pathol; 2005 Jan;13(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma.
  • In view of (1) the encapsulation and the uniformity of the constituent cells, (2) the negative or weak immunoreactivity for galectin-3 and HBME and negative to moderate immunoreactivity for CK19, and (3) the absence or paucity of nuclear criteria for the diagnosis of PTC and the absence of lymph node metastasis in all study cases, we believe that these lesions represent the papillary variant of oncocytic follicular adenoma (Hürthle cell adenoma).
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735853.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromatin
  •  go-up   go-down


37. Lundgren CI, Zedenius J, Skoog L: Fine-needle aspiration biopsy of benign thyroid nodules: an evidence-based review. World J Surg; 2008 Jul;32(7):1247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results were good, with only a few false-negative and false-positive results, but the problem of differentiating follicular adenoma from follicular carcinoma remained a significant problem.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2003 Summer;14(2):167-75 [12858008.001]
  • [Cites] Cytopathology. 2003 Dec;14(6):307-8 [14632726.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1410-6 [17534557.001]
  • [Cites] Endocr Pract. 2003 Mar-Apr;9(2):128-36 [12917075.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):712-8 [17151796.001]
  • [Cites] Cancer. 1997 Aug 25;81(4):253-9 [9292740.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):381-91 [17639052.001]
  • [Cites] Acta Cytol. 2001 Sep-Oct;45(5):669-74 [11575641.001]
  • [Cites] Thyroid. 2005 Mar;15(3):251-8 [15785244.001]
  • [Cites] Cancer. 2001 Aug 25;93(4):263-8 [11507700.001]
  • [Cites] Cancer. 2007 Oct 25;111(5):306-15 [17680588.001]
  • [Cites] Cytojournal. 2005 Jun 29;2(1):12 [15987502.001]
  • [Cites] Thyroid. 2001 Oct;11(10):973-6 [11716046.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Endocr Pract. 1997 Jan-Feb;3(1):9-13 [15251487.001]
  • [Cites] Cancer. 1989 Feb 15;63(4):718-25 [2914278.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Chir Ital. 2001 Sep-Oct;53(5):645-52 [11723895.001]
  • [Cites] World J Surg. 2000 Aug;24(8):907-12 [10865034.001]
  • [Cites] Chest. 1989 Feb;95(2 Suppl):2S-4S [2914516.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):541-4 [9797735.001]
  • [Cites] Monogr Clin Cytol. 1974;4(0):1-211 [4600327.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):282-9 [8420446.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Thyroid. 2007 Jul;17(7):635-8 [17696833.001]
  • [Cites] Cytopathology. 2003 Dec;14(6):327-31 [14632730.001]
  • [Cites] Surg Oncol. 2006 Dec;15(4):189-97 [17531743.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4924-7 [12414851.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):369-73 [14739493.001]
  • [Cites] Surg Clin North Am. 1979 Feb;59(1):3-18 [441906.001]
  • [Cites] Thyroid. 2006 Oct;16(10):1003-8 [17042686.001]
  • [Cites] Thyroid. 2003 Apr;13(4):371-80 [12812214.001]
  • [Cites] Am J Surg. 1983 Jul;146(1):72-8 [6869682.001]
  • [Cites] Diagn Cytopathol. 2006 Jan;34(1):67-76 [16355378.001]
  • [Cites] Clin Orthop Relat Res. 2007 Feb;455:3-5 [17340682.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):678-83 [17381488.001]
  • [Cites] Laryngoscope. 2006 Jan;116(1):154-6 [16481831.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Clin Lab Med. 1993 Sep;13(3):699-709 [8222583.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):48-52 [2521756.001]
  • (PMID = 18408965.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


38. McGregor D: Ethyl tertiary-butyl ether: a toxicological review. Crit Rev Toxicol; 2007 May;37(4):287-312
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In male rats only, TBA induced alpha(2u)-globulin nephropathy-related renal tubule adenomas.
  • In addition, increases in thyroid follicular cell adenoma incidence were associated with TBA treatment in female mice.

  • Hazardous Substances Data Bank. Methyl t-butyl ether .
  • Hazardous Substances Data Bank. Ethyl tert-butyl ether .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453936.001).
  • [ISSN] 1040-8444
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Ethyl Ethers; 0 / Methyl Ethers; 29I4YB3S89 / methyl tert-butyl ether; 3R9B16WR19 / ethyl tert-butyl ether
  • [Number-of-references] 128
  •  go-up   go-down


39. Jaffar R, Mohanty SK, Khan A, Fischer AH: Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms. Cytojournal; 2009;6:3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms.
  • BACKGROUND: Published criteria to distinguish benign colloid nodules from follicular neoplasms emphasize only three interdependent features: size of follicles, amount of colloid, and cellularity.
  • METHODS: This study quantified the significance of cystic change, defined as presence of macrophages, and the presence of hemosiderin in either the macrophages or follicular cells.
  • The cohort consisted of 165 patients with fine needle aspiration (FNA) and histologic follow-up of either goiter (101), follicular adenoma (47), or follicular carcinoma (17).
  • RESULTS: Hemosiderin within macrophages were seen in 67% (68 of 101) of the goiters and only 6% (four of 64) of follicular neoplasms (P<.0001).
  • All four follicular neoplasms with hemosiderin in macrophages were adenomas.
  • None of the 17 follicular carcinomas had hemosiderin in macrophages (P<.12).
  • Macrophages without hemosiderin also strongly distinguished goiters from neoplasms (83% vs 17%) but appears less useful as a criterion since macrophages were present within 3 of 17 follicular carcinomas.
  • Hemosiderin within follicular epithelial cells was present in 18% (18 of 101) of goiters, whereas none of the 64 follicular neoplasms had intraepithelial hemosiderin (P<.0003).
  • CONCLUSIONS: If papillary thyroid carcinoma and Hürthle cell neoplasm are ruled out, our findings indicate that the presence of hemosiderin virtually excludes a clinically significant follicular neoplasm.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytojournal. 2008;5:6 [18394201.001]
  • [Cites] Diagn Cytopathol. 2007 Aug;35(8):525-8 [17636488.001]
  • [Cites] Cytopathology. 2007 Apr;18(2):105-11 [17397495.001]
  • [Cites] Cytopathology. 1999 Jun;10(3):171-9 [10390065.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1083-90 [14606565.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):142-6 [1542996.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):53-60 [2916371.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1164-70 [3943039.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):345-51 [2343690.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • (PMID = 19495407.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2678825
  • [Keywords] NOTNLM ; Benign colloid nodule / follicular cells / hemosiderin laden macrophages / hemosiderin within follicular neoplasms / macrophages
  •  go-up   go-down


40. Bradly DP, Reddy V, Prinz RA, Gattuso P: Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery; 2009 Dec;146(6):1099-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of IPC was compared among patients with Hashimoto's thyroiditis, multinodular goiter, follicular adenoma, and Graves' disease.
  • RESULTS: Overall, 81 (12.0%) IPCs were recorded with decreasing order of frequency: Hashimoto's thyroiditis, follicular adenoma, goiter, and Graves' disease.
  • Contralateral IPC was detected in 6/15 (40%) patients with follicular adenoma.
  • IPC was encountered in the contralateral lobe in 40% of patients with follicular adenoma.
  • Total thyroidectomy may be considered an appropriate operative treatment in patients with Hashimoto's thyroiditis and follicular adenoma requiring operation owing to the high incidence and frequent contralateral involvement of IPC, respectively.
  • [MeSH-minor] Adenoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Chicago / epidemiology. Female. Goiter, Nodular / complications. Goiter, Nodular / surgery. Graves Disease / complications. Graves Disease / surgery. Hashimoto Disease / complications. Hashimoto Disease / surgery. Humans. Male. Middle Aged. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Multiple Primary / surgery. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958937.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Pisarek H, Stepień T, Kubiak R, Borkowska E, Pawlikowski M: Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res; 2009;2(1):1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.
  • It has been widely investigated their distribution in pituitary adenomas, brain tumors, adrenal tumors and neuroendocrine tumors in gastrointestinal tract (NET).
  • Results of SSTR 1-5 detection in other thyroid pathologies like follicular adenomas and papillary cancers are still scarce and often controversial, depending of investigation method used.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Regul Pept. 2007 Jan 10;138(1):32-9 [16996150.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Nov;283(5):E1056-66 [12376335.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2218-24 [16569735.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):69-78 [16601280.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2047-52 [9748118.001]
  • [Cites] J Endocrinol Invest. 1997 Jun;20(6):348-67 [9294784.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1579-82 [10188909.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2417-20 [9661621.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62 [9177396.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):427-42 [8521788.001]
  • [Cites] Trends Pharmacol Sci. 1995 Mar;16(3):86-8 [7792934.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 15;192(1):288-94 [8386508.001]
  • [Cites] Lab Invest. 1991 Apr;64(4):567-73 [1673164.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):451-8 [14713257.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):231-8 [14586068.001]
  • [Cites] Endokrynol Pol. 2006 May-Jun;57(3):238-43 [16832788.001]
  • (PMID = 19173713.001).
  • [ISSN] 1756-6614
  • [Journal-full-title] Thyroid research
  • [ISO-abbreviation] Thyroid Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2646698
  •  go-up   go-down


42. Aiad HA, Kandil MA, Asaad NY, El-Kased AM, El-Goday SF: Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst; 2008 Mar;20(1):36-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: This study included a total of 79 cases; 19 multinodular goiter (MNG), 19 follicular adenoma (FA), 13 follicular carcinoma (FTC) and 28 papillary carcinoma (PTC).
  • According to H score, glaectin-3 immunostaining was significantly lowered in FA) 1+/-2.8 as compared to papillary (158.5+/-88.6) and follicular carcinoma (150+/-83.9) (p>0.0001).
  • However, there was no statistically significant difference between FTC and PTC (p=0.56) or between classic and follicular variants of PTC (p=0.51).
  • CONCLUSION: We suggest Galectin-3 as a supplementary immunostaining in histological diagnosis of difficult thyroid follicular lesions and in preoperative evaluation of indeterminate thyroid cytology to avoid unnecessary aggressive surgical interference in benign lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847280.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


43. Yukinawa N, Oba S, Kato K, Taniguchi K, Iwao-Koizumi K, Tamaki Y, Noguchi S, Ishii S: A multi-class predictor based on a probabilistic model: application to gene expression profiling-based diagnosis of thyroid tumors. BMC Genomics; 2006;7:190
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: With four thyroid tissue types, i.e., papillary carcinoma, follicular carcinoma, follicular adenoma, and normal thyroid, we performed gene expression profiling with adaptor-tagged competitive PCR, a high-throughput RT-PCR technique.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 2000 Jan 4;241(1):125-31 [10607906.001]
  • [Cites] Bioinformatics. 2005 Nov 15;21(22):4148-54 [16174683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Genome Biol. 2003;4(3):R21 [12620106.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1061-9 [12801866.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1132-9 [12801874.001]
  • [Cites] Bioinformatics. 2003 Nov 1;19(16):2088-96 [14594714.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2429-37 [15087314.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):483-6 [716909.001]
  • [Cites] Tumori. 1993 Oct 31;79(5):314-20 [8116073.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 15;25(22):4694-6 [9358186.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D533-6 [15608255.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):56-65 [15640445.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):422-31 [15659489.001]
  • [Cites] Bioinformatics. 2005 Mar 1;21(5):631-43 [15374862.001]
  • [Cites] Anal Biochem. 2005 Apr 1;339(1):15-28 [15766705.001]
  • [Cites] Bioinformatics. 2005 Jun 1;21(11):2691-7 [15814557.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • (PMID = 16872506.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550728
  •  go-up   go-down


44. Kusakabe T, Kawaguchi A, Hoshi N, Kawaguchi R, Hoshi S, Kimura S: Thyroid-specific enhancer-binding protein/NKX2.1 is required for the maintenance of ordered architecture and function of the differentiated thyroid. Mol Endocrinol; 2006 Aug;20(8):1796-809
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To understand the role of T/ebp/Nkx2.1 in the adult thyroid, a thyroid follicular cell-specific conditional knockout (KO) mouse line, T/ebp(fl/fl);TPO-Cre, was established that expresses Cre recombinase under the human thyroid peroxidase (TPO) gene promoter.
  • These mice appeared to be healthy and exhibited loss of T/ebp/Nkx2.1 expression in many, but not all, thyroid follicular cells as determined by immunohistochemistry and real-time PCR, thus presenting a T/ebp-thyroid-conditional hypomorphic mice.
  • Detailed analysis of the thyroids from T/ebp(fl/fl), T/ebp(fl/fl);TPO-Cre, and T/ebp(fl/ko) mice, where the latter mouse line is derived from crosses with the original T/ebp/Nkx2.1-heterozygous mice, revealed that T/ebp(fl/fl);TPO-Cre mice can be classified into two groups with different phenotypes: one having atrophic/degenerative thyroid follicles with frequent presence of adenomas and extremely high serum TSH levels, and the other having an altered thyroid structure with reduced numbers of extraordinary dilated follicles consisting of excessive numbers of follicular cells as compared with those usually found in the normal thyroid.
  • In vitro three-dimensional thyroid primary cultures using thyroids from T/ebp(fl/fl);TPO-Cre, T/ebp(fl/ko), and T/ebp(fl/fl) mice, and the latter treated with recombinant adenovirus with and without Cre expression, demonstrated that only cells from T/ebp(fl/fl) mice without adeno-Cre treatment formed follicular structures.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2001 Jun;51(6):403-17 [11422801.001]
  • [Cites] Cell Motil Cytoskeleton. 2001 Mar;48(3):201-12 [11223951.001]
  • [Cites] J Endocrinol. 2002 May;173(2):345-55 [12010642.001]
  • [Cites] Mol Endocrinol. 2003 Nov;17(11):2295-302 [12907760.001]
  • [Cites] Genesis. 2004 Jul;39(3):212-6 [15282748.001]
  • [Cites] Cell Death Differ. 2004 Sep;11(9):1046-8 [15143348.001]
  • [Cites] EMBO J. 1989 Sep;8(9):2537-42 [2583123.001]
  • [Cites] Endocrinology. 1990 Apr;126(4):2027-34 [2180681.001]
  • [Cites] EMBO J. 1990 Nov;9(11):3631-9 [1976511.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6216-24 [2174102.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):4927-33 [1922026.001]
  • [Cites] Mol Cell Biol. 1992 Feb;12(2):576-88 [1732732.001]
  • [Cites] Development. 1990 Oct;110(2):643-51 [1723950.001]
  • [Cites] Mol Endocrinol. 1993 Dec;7(12):1589-95 [8145764.001]
  • [Cites] Exp Cell Res. 1994 Aug;213(2):319-26 [8050488.001]
  • [Cites] Mol Endocrinol. 1994 Aug;8(8):1049-69 [7997232.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):60-9 [8557195.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5860-5 [8650183.001]
  • [Cites] Eur J Endocrinol. 1997 Feb;136(2):128-36 [9116904.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3185-97 [9214635.001]
  • [Cites] Mol Endocrinol. 1997 Oct;11(11):1747-55 [9328356.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):1999-2006 [9528987.001]
  • [Cites] Dev Biol. 1998 Mar 1;195(1):1-15 [9520319.001]
  • [Cites] Biochim Biophys Acta. 1998 Mar 13;1396(3):336-48 [9545595.001]
  • [Cites] Nat Genet. 1998 May;19(1):87-90 [9590297.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):395-8 [9697704.001]
  • [Cites] Mol Cell Endocrinol. 1998 May 25;140(1-2):37-43 [9722166.001]
  • [Cites] Endocrinology. 1999 Mar;140(3):1094-103 [10067831.001]
  • [Cites] J Cell Sci. 1999 May;112 ( Pt 9):1405-16 [10194419.001]
  • [Cites] Dev Biol. 1999 May 1;209(1):60-71 [10208743.001]
  • [Cites] Thyroid. 1999 Apr;9(4):319-31 [10319936.001]
  • [Cites] Cell Death Differ. 1999 Jun;6(6):508-15 [10381653.001]
  • [Cites] Biochimie. 1999 Apr;81(4):321-7 [10401665.001]
  • [Cites] Dev Dyn. 2006 May;235(5):1300-9 [16342117.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1265-71 [10646670.001]
  • [Cites] Endocrinology. 2000 Apr;141(4):1403-13 [10746644.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;66:307-56 [11051768.001]
  • [Cites] Science. 2000 Dec 1;290(5497):1717-21 [11099404.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14376-81 [11121041.001]
  • [Cites] J Clin Invest. 2002 Feb;109(4):469-73 [11854318.001]
  • (PMID = 16601074.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC005522-20; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ NIHMS51053; NLM/ PMC2588428
  •  go-up   go-down


45. Letsas KP, Frangou-Lazaridis M, Skyrlas A, Tsatsoulis A, Malamou-Mitsi V: Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions. Pathol Int; 2005 Nov;55(11):694-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proliferation and apoptosis-related transcription factor immunoexpression patterns were concomitantly investigated in tissue sections of normal thyroid, goiters, follicular adenomas and well-differentiated papillary and follicular carcinomas using antibodies against prothymosin alpha, E2F-1, p53, Bcl2, and Bax proteins.
  • Prothymosin alpha and E2F-1 immunoexpression levels were found to be significantly elevated in well-differentiated carcinomas compared to adenomas, goiters and normal tissues (P < 0.05).
  • [MeSH-minor] Adenoma / pathology. Adenoma / physiopathology. Adolescent. Adult. Aged. Carcinoma, Papillary, Follicular / pathology. Carcinoma, Papillary, Follicular / physiopathology. DNA-Binding Proteins / analysis. DNA-Binding Proteins / immunology. DNA-Binding Proteins / physiology. E2F1 Transcription Factor / analysis. E2F1 Transcription Factor / immunology. E2F1 Transcription Factor / physiology. Female. Goiter / pathology. Goiter / physiopathology. Humans. Immunohistochemistry. Male. Middle Aged. Protein Precursors / analysis. Protein Precursors / immunology. Protein Precursors / physiology. Repressor Proteins / analysis. Repressor Proteins / immunology. Repressor Proteins / physiology. Thymosin / analogs & derivatives. Thymosin / analysis. Thymosin / immunology. Thymosin / physiology. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / immunology. Tumor Suppressor Protein p53 / physiology. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / immunology. Tumor Suppressor Proteins / physiology. bcl-2-Associated X Protein / analysis. bcl-2-Associated X Protein / immunology. bcl-2-Associated X Protein / physiology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271081.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BCLAF1 protein, human; 0 / DNA-Binding Proteins; 0 / E2F1 Transcription Factor; 0 / Protein Precursors; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 0 / prothymosin alpha; 61512-21-8 / Thymosin
  •  go-up   go-down


46. Ludvíková M, Holubec L Jr, Ryska A, Topolcan O: Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining. Anticancer Res; 2005 May-Jun;25(3A):1835-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The differential diagnosis of well-differentiated tumors of follicular cell origin remains a most problematic task in thyroid pathology.
  • RESULTS: Carcinomas generally showed significantly higher PI than adenomas, irrespective of their oncocytic or non-oncocytic features.
  • Moreover, PI in oncocytic adenomas was significantly higher than in non-oncocytic ones.
  • Oncocytic adenomas have higher malignant potential and should be promptly surgically removed.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033110.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


47. Lozano-Gómez MJ, Sánchez-Blanco JM, Vázquez-Morón M, Parra-Membrives P, Torres-Arcos C, Jurado-Jiménez R, Gómez-Rubio D, Recio-Moyano G: [Hemithyroidectomy in a unilateral goiter: a valid therapeutic option. Review of the contralateral hemithyroid ten years after treatment]. Cir Esp; 2006 Jul;80(1):23-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to evaluate the remaining thyroid in patients with NG compared with those with follicular adenoma who underwent hemithyroidectomy.
  • Patients with follicular adenoma (with normal contralateral ultrasonography) who underwent hemithyroidectomy during the same period were selected to form the control group (CG).

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796949.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


48. Bufalo NE, Leite JL, Guilhen AC, Morari EC, Granja F, Assumpcao LV, Ward LS: Smoking and susceptibility to thyroid cancer: an inverse association with CYP1A1 allelic variants. Endocr Relat Cancer; 2006 Dec;13(4):1185-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 248 patients with thyroid nodules, including 67 benign goiters, 13 follicular adenomas, 136 papillary carcinomas, and 32 follicular carcinomas, and 277 controls with similar ethnic backgrounds were interviewed on their lifetime dietary and occupational histories, smoking habit, previous diseases, and other anamnestic data.


49. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW: Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol; 2008 Mar;158(3):375-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We used tissue arrays containing 177 thyroid tissues: 100 benign tissues (including normal thyroid, Graves disease, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)).
  • Gal-3, FN-1, and iNIS had the highest accuracy in the differential diagnosis of follicular lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299472.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CITED1 protein, human; 0 / Fibronectins; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; 0 / Nuclear Proteins; 0 / PPAR gamma; 0 / Symporters; 0 / Transcription Factors; 0 / sodium-iodide symporter
  •  go-up   go-down


50. Asioli S, Bussolati G: Emerin immunohistochemistry reveals diagnostic features of nuclear membrane arrangement in thyroid lesions. Histopathology; 2009 Apr;54(5):571-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Immunohistochemistry of the NM with emerin as well as three-dimensional reconstruction of the images (through deconvolution processing) performed on a series of 54 cases (processed following the tissue array procedure) revealed a uniform arrangement of the NM in non-neoplastic lesions (thyroiditis, microfollicular goitre, follicular adenoma) and normal thyroid as well as in follicular carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302538.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / emerin
  •  go-up   go-down


51. Zhao J, Leonard C, Gemsenjäger E, Heitz PU, Moch H, Odermatt B: Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling. Oncol Rep; 2008 Feb;19(2):329-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling.
  • It is difficult to distinguish benign from malignant follicular thyroid tumors by histological or cytological examination.
  • The goal of this study was to reveal gene expression variations between benign and malignant follicular lesions of the thyroid gland.
  • We investigated gene expression profiles from 24 follicular thyroid tumors (12 carcinomas and 12 adenomas) and 13 normal thyroid tissues using high-density human cDNA arrays.
  • Expression patterns of a set of known genes were found to be significantly different between follicular adenomas and follicular carcinomas.
  • Our results demonstrate a potential use of gene expression profiling for differentiating benign from malignant follicular thyroid tumors.
  • A detailed investigation of the differentially expressed genes could give new insights into molecular pathways of malignant transformation of thyroid follicular neoplasm and may help to develop a molecular tool for the preoperative differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Gene Expression Profiling. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202778.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


52. Larsen KK, Andersen NF, Melsen F, Sørensen FB: Vascularity in thyroid neoplasms: a methodological investigation with a view to diagnostics. APMIS; 2006 Nov;114(11):749-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study had a retrospective design and involved 24 follicular adenomas (FA), 19 follicular carcinomas (FC), and 17 papillary carcinomas (PC).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17078854.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


53. Reddi HV, Madde P, Marlow LA, Copland JA, McIver B, Grebe SK, Eberhardt NL: Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease Prognosis. Genes Cancer; 2010 May;1(5):480-492
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PAX8/PPARγ fusion protein (PPFP) occurs in 36% of human follicular thyroid carcinoma (FTC) and is associated with favorable prognosis.
  • Immunohistochemical staining of archival human thyroid tumors demonstrates a significant decrease in CD31 staining in all adenomas and carcinomas containing the PAX8/PPARγ rearrangement.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20827445.001).
  • [ISSN] 1947-6019
  • [Journal-full-title] Genes & cancer
  • [ISO-abbreviation] Genes Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA080117-08; United States / NCI NIH HHS / CA / R01 CA080117
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


54. Zhang B, Jiang YX, Liu JB, Yang M, Dai Q, Zhu QL, Gao P: Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules. Thyroid; 2010 Jan;20(1):51-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all, there were 104 nodules (47 papillary carcinomas, 3 medullary carcinomas, 1 metastatic carcinoma, 44 hyperplasia nodule, 7 follicular adenomas, 1 suture granulomas, and 1 Hashimoto's disease).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067379.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


55. Anderson L, Middleton WD, Teefey SA, Reading CC, Langer JE, Desser T, Szabunio MM, Mandel SJ, Hildebolt CF, Cronan JJ: Hashimoto thyroiditis: Part 2, sonographic analysis of benign and malignant nodules in patients with diffuse Hashimoto thyroiditis. AJR Am J Roentgenol; 2010 Jul;195(1):216-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among nodules within diffuse Hashimoto thyroiditis, 84% (69/82) were benign (35 nodular Hashimoto thyroiditis, 32 nodular hyperplasia, and two follicular adenoma), and 16% (13/82) were malignant (12 papillary carcinoma and one lymphoma).

  • Genetic Alliance. consumer health - Hashimoto's Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20566819.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


56. Wasko R, Michalek K, Pacholska J, Obrepalska-Steplowska A, Gozdzicka-Jozefiak A, Sowinski J: Clinical significance of the insulin-like growth factor I gene promoter (P1) polymorphism in thyroid nodular disease. Neuro Endocrinol Lett; 2005 Dec;26(6):699-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our study we revealed no significant difference between carcinomatous and non-carcinomatous groups of patients in terms of presence of nucleotide change, but Fisher's exact test gave a significant result in terms of the efficacy of detecting follicular adenoma.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / genetics. Carcinoma / diagnosis. Goiter / genetics. Insulin-Like Growth Factor I / genetics. Thyroid Nodule / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380677.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


57. Pagedar NA, Chen DH, Wasman JK, Savvides P, Schluchter MD, Wilhelm SM, Lavertu P: Molecular classification of thyroid nodules by cytology. Laryngoscope; 2008 Apr;118(4):692-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preliminary analysis using fluorometry and reverse-transcriptase (RT)-PCR was performed.
  • RT-PCR revealed satisfactory RNA recovery in all other specimens. qPCR showed significant over-expression of fibronectin in the papillary carcinomas compared with the goiters (P = .0013), follicular adenomas (P = .0014), and follicular carcinomas (P = .0001).
  • Differences in both fibronectin and MUC1 expression between the follicular carcinomas and the follicular adenomas were also significant (P = .025 and .045, respectively).
  • Both fibronectin and MUC1 were differentially expressed in follicular adenomas and follicular carcinomas, and fibronectin expression differed in papillary carcinomas compared with the other lesions.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Antigens, CD3 / analysis. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Papillary / pathology. Cell Adhesion Molecules / analysis. Feasibility Studies. Fibronectins / analysis. Galectin 3 / analysis. Gene Expression Regulation, Neoplastic / genetics. Goiter / pathology. Humans. Molecular Biology. Mucin-1 / analysis. Polymerase Chain Reaction. Prospective Studies. Protein-Tyrosine Kinases / analysis. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-met. Receptors, Growth Factor / analysis. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094649.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Fibronectins; 0 / Galectin 3; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 0 / tumor-associated antigen GA733; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


58. Braunschweig T, Kaserer K, Chung JY, Bilke S, Krizman D, Knezevic V, Hewitt SM: Proteomic expression profiling of thyroid neoplasms. Proteomics Clin Appl; 2007 Mar;1(3):264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differentiating benign neoplasms such as follicular adenomas from malignant entities such as follicular carcinomas and papillary carcinoma can be challenging.
  • To define the proteomic profile of different thyroid tumors, we screened an antibody array of 330 features against five thyroid neoplasms: follicular adenoma, follicular carcinoma, papillary carcinoma, anaplastic carcinoma, and medullary carcinoma as well as normal thyroid epithelium.
  • Analysis revealed c-erbB-2, Annexin IV, and Stat5a have potential clinical utility to differentiate follicular adenoma, follicular carcinoma, and papillary carcinoma from each other.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 21136677.001).
  • [ISSN] 1862-8346
  • [Journal-full-title] Proteomics. Clinical applications
  • [ISO-abbreviation] Proteomics Clin Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Sidoti M, Marino G, Resmini E, Augeri C, Cappi C, Cavallero D, Lagasio C, Ceppa P, Minuto F, Giusti M: The rational use of fine needle aspiration biopsy (FNAB) in diagnosing thyroid nodules. Minerva Endocrinol; 2006 Jun;31(2):159-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DTC was detected in 100% of these cases (1 follicular carcinoma, 1 insular carcinoma, 9 papillary carcinoma).
  • Of the 2 Thy 3 cases, 1 was follicular carcinoma and 1 was follicular adenoma with adjacent papillary carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682939.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


60. Liu FH, Hsueh C, Chang HY, Liou MJ, Huang BY, Lin JD: Sonography and fine-needle aspiration biopsy in the diagnosis of benign versus malignant nodules in patients with autoimmune thyroiditis. J Clin Ultrasound; 2009 Nov-Dec;37(9):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULT: Twenty-four of the 40 nodules were malignant, including 20 papillary carcinomas, 3 follicular carcinomas, and 1 medullary carcinoma.
  • Of the 16 benign nodules, 8 were nodular hyperplasia, 6 lymphocytic thyroiditis, and 1 each follicular adenoma and Hürthle cell adenoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley Periodicals, Inc. J Clin Ultrasound, 2009.
  • (PMID = 19750546.001).
  • [ISSN] 1097-0096
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Pérez-Ruiz L, Ros-López S, Gudelis M, Latasa-Gimeno JA, Artigas-Marco C, Pelayo-Salas A: Isthmectomy: a conservative operation for solitary nodule of the thyroid isthmus. Acta Chir Belg; 2008 Nov-Dec;108(6):699-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination showed nodular hyperplasia in 29 cases, follicular adenoma in 1 and papillary thyroid carcinoma in 1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241921.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


62. Reimann JD, Dorfman DM, Nosé V: Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study: evidence of thymic differentiation and solid cell nest origin. Am J Surg Pathol; 2006 Aug;30(8):994-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven CASTLE, 11 SCNs, 10 thymic carcinoma, 11 invasive thymoma, 12 thymoma, 28 papillary thyroid carcinoma, 4 thyroid squamous cell carcinoma, 2 childhood sclerosing carcinoma, 4 follicular adenoma, 6 follicular carcinoma, 4 poorly differentiated carcinoma, and 20 lymphocytic thyroiditis cases were analyzed.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861971.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Carcinoembryonic Antigen; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


63. Pennelli N, Pennelli G, Merante Boschin I, Pelizzo MR: Thyroid intrafollicular neoplasia (TIN) as a precursor of papillary microcarcinoma. Ann Ital Chir; 2005 May-Jun;76(3):219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SERIES: In a retrospective study on a total of 105 cases, occult or incidental thyroid papillary microcarcinoma was found in association with multinodular goiter (52%), chronic thyroiditis (19%), follicular adenoma (19%), parathyroid neoplasia (5%), and no evident thyroid pathology (5%).
  • RESULTS: Atypical follicles are described in various pathological conditions correlating with lymphoid inflammatory infiltration, stromal sclerosis, and hyperplastic or neoplastic follicular nodules.
  • CONCLUSIONS: The atypical features of follicular epithelial areas make up a wide spectrum that starts with the dispersion of nuclear chromatin.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16355851.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


64. Lassalle S, Hofman V, Marius I, Gavric-Tanga V, Brest P, Havet K, Butori C, Selva E, Santini J, Mograbi B, Hofman P: Assessment of morphology, antigenicity, and nucleic acid integrity for diagnostic thyroid pathology using formalin substitute fixatives. Thyroid; 2009 Nov;19(11):1239-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Calibrated specimens (200 mg, 1 cm(2) each) from four conventional papillary thyroid carcinomas, four follicular variant of papillary thyroid carcinomas, three minimally invasive follicular carcinomas, four thyroid adenomas, five thyroid nodular hyperplasias, and five normal thyroid tissues were fixed for 6, 12, or 24 hours, in different fixatives (formalin, Glyo-Fixx, FineFIX, ExcellPlus, RCL2) at room temperature or at 4 degrees C.

  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19888862.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fixatives; 0 / Nucleic Acids
  •  go-up   go-down


65. Fontaine JF, Mirebeau-Prunier D, Raharijaona M, Franc B, Triau S, Rodien P, Goëau-Brissonniére O, Karayan-Tapon L, Mello M, Houlgatte R, Malthiery Y, Savagner F: Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers. PLoS One; 2009;4(10):e7632
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To improve diagnostic relevance, we have simultaneously analyzed microarray data from six public datasets covering a total of 347 thyroid tissue samples representing 12 histological classes of follicular lesions and normal thyroid tissue.
  • Focusing on four subclasses of follicular tumor, we explored the diagnostic potential of 12 selected markers (CASP10, CDH16, CLGN, CRABP1, HMGB2, ALPL2, ADAMTS2, CABIN1, ALDH1A3, USP13, NR2F2, KRTHB5) by real-time quantitative RT-PCR on 32 other new samples.
  • The gene expression profiles of follicular tumors were examined with reference to the mutational status of the Pax8-PPARgamma, TSHR, GNAS and NRAS genes.
  • Our approach was particularly relevant for the classification of microfollicular adenomas.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 May 10;104(6):735-44 [12640681.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005 [14764826.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2429-40 [15073121.001]
  • [Cites] Thyroid. 2004 Mar;14(3):207-15 [15072703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Head Neck. 2004 Dec;26(12):1069-83 [15515157.001]
  • [Cites] Surgery. 2004 Dec;136(6):1160-8 [15657571.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):1163-70 [15522933.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2512-21 [15713710.001]
  • [Cites] J Endocrinol Invest. 2005 Feb;28(2):106-12 [15887854.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):223-31 [15972966.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W460-4 [15980512.001]
  • [Cites] Cancer Lett. 2005 Sep 8;227(1):59-73 [16051032.001]
  • [Cites] Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3):513-24 [16164832.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6902-16 [16027733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3114-9 [16540661.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):385-93 [16506015.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93 [16609007.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1934-42 [16407496.001]
  • [Cites] BMC Genomics. 2006;7:190 [16872506.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):225-34 [17308359.001]
  • [Cites] Cell Oncol. 2007;29(3):195-209 [17452772.001]
  • [Cites] Oncogene. 2007 Dec 13;26(57):7894-903 [17621275.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1572-80 [18316623.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2228-36 [17968324.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1600-8 [18270258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7821-6 [18509053.001]
  • [Cites] J Exp Med. 2008 Jul 7;205(7):1673-85 [18559453.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3286-94 [18593772.001]
  • [Cites] J Interferon Cytokine Res. 2008 Dec;28(12):733-40 [18937547.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):283-92 [19016304.001]
  • [Cites] Hum Pathol. 2008 Nov;39(11):1656-63 [18657294.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Thyroid. 2000 Sep;10(9):761-5 [11041453.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Aug;55(2):143-58 [11531919.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Genome Biol. 2002 Jun 25;3(7):RESEARCH0036 [12184810.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • (PMID = 19893615.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Genetic Markers; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  • [Other-IDs] NLM/ PMC2764086
  •  go-up   go-down


66. Tuttle RM, Lukes Y, Onstad L, Lushnikov E, Abrosimov A, Troshin V, Tsyb A, Davis S, Kopecky KJ, Francis G: ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout. Thyroid; 2008 Aug;18(8):839-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This pilot study included adults and children diagnosed with PTC (n = 76) and children diagnosed with follicular adenomas (n = 24) during May 1986 through December 1999, who were living in the Bryansk Oblast of the Russian Federation at the time of the Chernobyl accident, who had paraffin-embedded thyroid surgical samples available and for whom an individual dose to the thyroid could be estimated.
  • The frequency of ret/PTC activation was determined using RT-PCR analysis.
  • RESULTS: ret/PTC oncogene activation was detected in 23.8% (5/21) and 14.5% (8/55) of the childhood and adult PTC cases, respectively, and 8.3% (2/24) of the follicular adenoma cases.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4232-8 [10566678.001]
  • [Cites] Radiat Res. 2006 Aug;166(2):367-74 [16881738.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1170-5 [10720057.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1093-103 [10741739.001]
  • [Cites] Cytogenet Cell Genet. 2000;88(1-2):56-61 [10773666.001]
  • [Cites] Semin Nucl Med. 2000 Apr;30(2):133-40 [10787193.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6 [11443191.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • [Cites] Int J Surg Pathol. 2002 Jan;10(1):15-22 [11927965.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3941-6 [12161537.001]
  • [Cites] Radiat Prot Dosimetry. 2004;108(2):143-60 [14978294.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2281-9 [15126554.001]
  • [Cites] Radiat Res. 2004 Sep;162(3):241-8 [15332999.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4280-4 [15356022.001]
  • [Cites] J Clin Invest. 1992 May;89(5):1517-22 [1569189.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):2940-3 [8319199.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):259 [7913169.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5617-20 [7585643.001]
  • [Cites] Oncogene. 1995 Dec 21;11(12):2459-67 [8545102.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3360-5 [8784097.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):95-100 [9001272.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1690-4 [9135009.001]
  • [Cites] Oncogene. 1997 Sep;15(11):1263-73 [9315093.001]
  • [Cites] Biochimie. 1997 Oct;79(9-10):619-23 [9466701.001]
  • [Cites] Thyroid. 1998 Feb;8(2):133-9 [9510121.001]
  • [Cites] Radiat Res. 1998 Sep;150(3):349-56 [9728663.001]
  • [Cites] Thyroid. 1998 Nov;8(11):1003-8 [9848713.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):32-8 [9935226.001]
  • [Cites] Lab Invest. 2004 Dec;84(12):1557-70 [15502856.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2364-9 [15671095.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):724-32 [15900042.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):897-903 [16818853.001]
  • [Cites] Oncogene. 2000 Jan 20;19(3):438-43 [10656692.001]
  • (PMID = 18690796.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human
  • [Other-IDs] NLM/ PMC2857448
  •  go-up   go-down


67. Muto S, Kasahara H, Yokoi R, Hayashi M, Souma S, Kobayashi K, Tamura T, Murakami M, Kuroda J, Shibata N: [Toxicity profile of silodosin (KMD-3213)]. Yakugaku Zasshi; 2006 Mar;126 Spec no.:247-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In carcinogenicity studies, mammary gland tumors and pituitary adenomas were increased in female mice given 150 mg/kg/day or more and 400 mg/kg/day respectively, while thyroid follicular cell carcinoma was increased in male rats given 150 mg/kg/day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518090.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Indoles; CUZ39LUY82 / silodosin
  •  go-up   go-down


68. Bukhari MH, Niazi S, Hanif G, Qureshi SS, Munir M, Hasan M, Naeem S: An updated audit of fine needle aspiration cytology procedure of solitary thyroid nodule. Diagn Cytopathol; 2008 Feb;36(2):104-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 30 cases (39.47%) of benign lesions, comprising of colloid goiter, follicular adenoma, and diffuse hyperplasia.
  • Only 9 cases (11.84%) were clearly committed as malignant lesions, comprising of papillary carcinoma, anaplastic carcinoma and suggestive of follicular carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18181183.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Raghay K, García-Caballero T, Nogueiras R, Morel G, Beiras A, Diéguez C, Gallego R: Ghrelin localization in rat and human thyroid and parathyroid glands and tumours. Histochem Cell Biol; 2006 Mar;125(3):239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid carcinomas (medullar, follicular and papillary) and parathyroid adenomas also showed intense and diffuse immunostaining for ghrelin.
  • These data provide direct morphological evidence that ghrelin may well be acting in a paracrine fashion in the regulation of thyroid follicular cell function.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):879-87 [12574228.001]
  • [Cites] J Endocrinol. 2002 Oct;175(1):201-9 [12379504.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):881-7 [11158061.001]
  • [Cites] Biochim Biophys Acta. 2001 Nov 11;1522(1):62-5 [11718902.001]
  • [Cites] FEBS Lett. 2003 Feb 11;536(1-3):173-9 [12586359.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 26;280(3):904-7 [11162609.001]
  • [Cites] Life Sci. 2004 Sep 17;75(18):2193-201 [15325845.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 May;280(5):R1483-7 [11294772.001]
  • [Cites] Neuroendocrinology. 2003 Feb;77(2):91-9 [12624530.001]
  • [Cites] Nature. 1999 Dec 9;402(6762):656-60 [10604470.001]
  • [Cites] Eur J Endocrinol. 2004 Aug;151(2):233-40 [15296479.001]
  • [Cites] J Endocrinol. 2002 Mar;172(3):R7-11 [11874717.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):4154-7 [11517195.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4284-91 [11549663.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4255-61 [11089560.001]
  • [Cites] Eur J Endocrinol. 2002 Jul;147(1):159-63 [12088933.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21995-2000 [10801861.001]
  • [Cites] Diabetes. 2002 Jan;51(1):124-9 [11756331.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 19;309(2):464-8 [12951072.001]
  • [Cites] Science. 1996 Aug 16;273(5277):974-7 [8688086.001]
  • [Cites] Circulation. 2001 Oct 23;104(17):2034-8 [11673342.001]
  • [Cites] Endocrinology. 2002 Feb;143(2):484-91 [11796502.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4984-90 [11600575.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1594-602 [12639944.001]
  • [Cites] Am J Med Genet. 1995 Jan 2;55(1):33-7 [7702094.001]
  • [Cites] Endocrinology. 2002 Feb;143(2):717-25 [11796529.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4325-8 [11089570.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):415-23 [9092793.001]
  • [Cites] Neuron. 2003 Feb 20;37(4):649-61 [12597862.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):788-94 [11159851.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5667-74 [11724768.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):213-6 [11119706.001]
  • [Cites] J Endocrinol. 2000 Apr;165(1):139-46 [10750044.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):780-5 [11688975.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):853-7 [12574224.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 5;276(3):905-8 [11027567.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):645-54 [12547722.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2988 [12050285.001]
  • [Cites] Endocrinology. 2001 Oct;142(10):4163-9 [11564668.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):5089-97 [12959995.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1300-8 [11889202.001]
  • (PMID = 16187069.001).
  • [ISSN] 0948-6143
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Ghrelin; 0 / Peptide Hormones; 0 / RNA, Messenger
  •  go-up   go-down


70. Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M: Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene; 2006 Aug 31;25(39):5467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.
  • To verify the role played by N-ras in thyroid carcinogenesis, we generated transgenic mice in which a human N-ras(Gln61Lys) oncogene (Tg-N-ras) was expressed in the thyroid follicular cells.
  • Tg-N-ras mice developed thyroid follicular neoplasms; 11% developed follicular adenomas and approximately 40% developed invasive follicular carcinomas, in some cases with a mixed papillary/follicular morphology.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / pathology. Amino Acid Substitution. Animals. Cell Differentiation. Humans. Mice. Mice, Transgenic. Neoplasm Invasiveness


71. Wang SL, Wu MT, Yang SF, Chan HM, Chai CY: Computerized nuclear morphometry in thyroid follicular neoplasms. Pathol Int; 2005 Nov;55(11):703-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized nuclear morphometry in thyroid follicular neoplasms.
  • Differential diagnosis of follicular adenoma (FA) and follicular carcinoma (FC) of the thyroid can be challenging in the routine practice of surgical pathology because the diagnosis of FC is strictly defined and identification depends on the presence of invasion of the capsule or blood vessels.
  • The present study investigated the diagnostic role of objective computerized nuclear morphometry in follicular neoplasms.
  • [MeSH-major] Adenocarcinoma, Follicular / ultrastructure. Adenoma / ultrastructure. Cell Nucleus / ultrastructure. Thyroid Neoplasms / ultrastructure

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271082.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


72. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • The purpose of our study was to evaluate IMP3 expression in thyroid follicular lesions, to determine whether it has a role in differentiating among these lesions, and to understand their biological relationships.
  • We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten Hürthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 Hürthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma.
  • No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):304-15 [18223334.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Cancer. 2008 Feb 25;114(1):49-56 [18098206.001]
  • [Cites] World J Surg. 2000 Aug;24(8):913-22 [10865035.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1178-83 [17521698.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):95-9 [10525192.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [16082252.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):70-4 [16614712.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):882-7 [10955455.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] Acta Cytol. 2008 Mar-Apr;52(2):133-8 [18499984.001]
  • [Cites] Virchows Arch. 1998 May;432(5):427-32 [9645441.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2676-82 [18412154.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):295-309 [16627917.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):699-701 [12618877.001]
  • [Cites] Pathol Res Pract. 2000;196(8):533-40 [10982016.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):109-17 [17159243.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


73. Yang J, Schnadig V, Logrono R, Wasserman PG: Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer; 2007 Oct 25;111(5):306-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytologic diagnoses were classified as unsatisfactory, benign, atypical cellular lesion (ACL), follicular neoplasm (FN), suspicious for malignancy, and positive for malignancy.
  • Sources of errors included diagnoses on inadequate specimens, sample errors, and overlapping cytologic features between hyperplastic nodules and follicular adenoma.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680588.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Ito Y, Akinaga A, Yamanaka K, Nakagawa T, Kondo A, Dickson RB, Lin CY, Miyauchi A, Taniguchi N, Miyoshi E: Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation. Glycobiology; 2006 May;16(5):368-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although neither GnT-V nor matriptase was expressed in normal thyroid tissue, positive staining for matriptase and GnT-V was observed in 52/68 and 66/68 cases of papillary carcinoma, 3/23 and 10/23 cases of follicular carcinoma, 5/13 and 9/13 cases of follicular adenoma, and 11/28 and 6/28 cases of anaplastic carcinoma, respectively.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16464868.001).
  • [ISSN] 0959-6658
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA096851
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.155 / alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / matriptase
  •  go-up   go-down


75. de Souza Meyer EL, Dora JM, Wagner MS, Maia AL: Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma. Clin Endocrinol (Oxf); 2005 Jun;62(6):672-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • D1 expression was determined by reverse transcription polymerase chain reaction (RT-PCR) and enzymatic assay.
  • PATIENTS: Tumours and adjacent normal tissues were obtained from 28 unselected patients (papillary carcinoma, n = 14; follicular adenoma, n = 7; follicular carcinoma, n = 6; anaplastic carcinoma, n = 1).
  • By contrast, significantly higher D1 mRNA levels and enzyme activity were present in follicular adenoma (1.9 +/- 1.5 vs. 0.83 +/- 0.58 AU, P = 0.028 and 2.67 +/- 1.42 vs. 0.22 +/- 0.06 pmol T4/min/mg protein, P = 0.044, respectively) and in follicular thyroid carcinoma (FTC) than in surrounding normal tissue (1.2 +/- 0.46 vs. 0.67 +/- 0.18 AU, P = 0.038 and 1.20 +/- 0.58 vs. 0.20 +/- 0.10 pmol T4/min/mg protein, P < 0.001, respectively).
  • [MeSH-minor] Adenoma / chemistry. Adult. Aged. Carcinoma / chemistry. Carcinoma, Papillary, Follicular / chemistry. Female. Humans. Linear Models. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943828.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.- / iodothyronine deiodinase type I; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


76. Brzeziańska E, Cyniak-Magierska A, Sporny S, Pastuszak-Lewandoska D, Lewiński A: Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions. Neuro Endocrinol Lett; 2007 Aug;28(4):341-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Thirty five (35) tissue samples were analysed: 24 cases of PTC, 4 cases of medullary thyroid carcinoma (MTC), 4 cases of follicular adenoma (FA) and 3 cases of nodular goitre (NG).
  • In real-time polymerase chain reaction (real-time PCR), two-step RT-PCR (reverse transcriptase-polymerase chain reaction) in an ABI PRISM 7500 Sequence Detection System was employed.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy. Cyclin D. Female. Gene Expression Regulation, Neoplastic. Goiter, Nodular / diagnosis. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693985.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin D; 0 / Cyclins
  •  go-up   go-down


77. Lacroix L, Michiels S, Mian C, Arturi F, Caillou B, Filetti S, Schlumberger M, Bidart JM: HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism. Clin Endocrinol (Oxf); 2006 Apr;64(4):398-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We examined the expression levels of transcription factors involved in thyroid development [thyroid transcription factor 1 (TTF-1), paired box gene 8 (PAX-8) and haematopoietically expressed homeobox (HEX)] in 101 thyroid tissues, including 14 normal thyroid tissues, 13 hyperfunctioning tissues, 27 benign adenomas and 47 follicular or papillary carcinomas.

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584511.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HHEX protein, human; 0 / Homeodomain Proteins; 0 / Iodides; 0 / Nuclear Proteins; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


78. Krause K, Eszlinger M, Gimm O, Karger S, Engelhardt C, Dralle H, Fuhrer D: TFF3-based candidate gene discrimination of benign and malignant thyroid tumors in a region with borderline iodine deficiency. J Clin Endocrinol Metab; 2008 Apr;93(4):1390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Quantitative real-time PCR was performed for CCND2, PLAB, PCSK2, HGD1, TFF3, B4GALT, LGALS3, ETS1, ADM3, and TG in 150 thyroid specimens, including 52 benign thyroid nodules (28 follicular adenoma and 24 adenomatous nodules), 52 corresponding normal thyroid tissues, 20 follicular carcinomas, 20 papillary carcinomas, and six undifferentiated carcinomas.
  • Using two-marker gene sets, we identified 11 combinations, which allowed both a distinction of benign and malignant thyroid nodules and a discrimination of follicular adenoma and carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18198227.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 0 / RNA, Messenger; 0 / TFF3 protein, human; 9679TC07X4 / Iodine
  •  go-up   go-down


79. Amended final report on the safety assessment of polyacrylamide and acrylamide residues in cosmetics. Int J Toxicol; 2005;24 Suppl 2:21-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acrylamide was a tumor initiator, but not an initiator/promoter, in two different mouse strains at a total dose of 300 mg/kg (6 doses over 2 weeks) resulting in increased lung adenomas and carcinomas without promotion.
  • In one study, increased incidence of mammary gland tumors, glial cell tumors, thyroid gland follicular tumors, oral tissue tumors, uterine tumors and clitoral gland tumors were noted in female rats.
  • Tumors of the scrotum in male rats were confirmed, as were the thyroid gland follicular tumors in males and females.

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • Hazardous Substances Data Bank. POLYACRYLAMIDE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16154914.001).
  • [ISSN] 1091-5818
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Acrylic Resins; 0 / Cosmetics; 0 / Irritants; 0 / Teratogens; 9003-05-8 / polyacrylamide
  • [Number-of-references] 99
  •  go-up   go-down


80. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S: Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol; 2007 Aug;88(4):271-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunostaining for VEGF and VEGF receptors was performed in 66 specimens of thyroid tissue, comprising 17 multinodular goitre (MNG), 14 Graves' disease, 10 follicular adenoma, 8 Hashimoto's thyroiditis, 7 papillary carcinoma and 10 normal thyroid specimens.
  • Using an immunostaining intensity cut off of 2, increased thyrocyte staining was seen in follicular adenoma specimens, MNG and normal thyroids compared with Hashimoto's thyroiditis and Graves' disease (P < 0.05).

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] J Endocrinol. 1998 Apr;157(1):5-12 [9614352.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):477-81 [7531224.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12 [7563203.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1569-79 [7478581.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):193-204 [8534867.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Surgery. 1996 Mar;119(3):333-9 [8619189.001]
  • [Cites] Mod Pathol. 1996 Jun;9(6):636-41 [8782200.001]
  • [Cites] J Surg Oncol. 1996 Oct;63(2):95-8 [8888801.001]
  • [Cites] J Natl Cancer Inst. 1997 Jan 15;89(2):139-47 [8998183.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):206-13 [9010092.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1968-73 [9177415.001]
  • [Cites] Br J Cancer. 1997;76(7):930-4 [9328154.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3741-7 [9360534.001]
  • [Cites] Br J Cancer. 1997;76(9):1221-7 [9365173.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):513-7 [9374227.001]
  • [Cites] J Pathol. 1998 Jan;184(1):53-7 [9582527.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1967-76 [10595926.001]
  • [Cites] Thyroid. 2000 Apr;10(4):349-57 [10807064.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):439-42 [10821490.001]
  • [Cites] J Endocrinol. 2000 Sep;166(3):475-80 [11029748.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):227-35 [11176129.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):10-7 [11172289.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):656-8 [11158026.001]
  • [Cites] IUBMB Life. 2001 Jul;52(1-2):61-6 [11795595.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6B):4221-9 [11908675.001]
  • [Cites] Biol Chem. 2002 Oct;383(10):1573-9 [12452433.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7284-90 [12499271.001]
  • [Cites] J Mol Med (Berl). 2003 Jan;81(1):20-31 [12545246.001]
  • [Cites] Endocrinology. 2004 Feb;145(2):817-22 [14605010.001]
  • [Cites] Thyroid. 2006 Jun;16(6):545-54 [16839256.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):931-44 [16954441.001]
  • [Cites] Lancet. 1992 Nov 7;340(8828):1120-4 [1279332.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Endocrinology. 1978 Dec;103(6):2306-14 [748050.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):18-32 [1372863.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1343-8 [9769366.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3908-12 [9814467.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):442-7 [9874430.001]
  • [Cites] Eur Urol. 1999 Jan;35(1):2-8 [9933788.001]
  • [Cites] J Endocrinol. 1999 Apr;161(1):41-9 [10194527.001]
  • [Cites] Hum Pathol. 1999 Aug;30(8):891-7 [10452500.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 May;115(5):1007-14 [9605068.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(11):651-6 [7525593.001]
  • (PMID = 17696908.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2517322
  •  go-up   go-down


81. Hasumura M, Imai T, Takizawa T, Ueda M, Onose J, Hirose M: Promotion of thyroid carcinogenesis by para-aminobenzoic acid in rats initiated with N-bis(2-hydroxypropyl)nitrosamine. Toxicol Sci; 2005 Jul;86(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final incidence of thyroid follicular cell adenomas and adenocarcinomas was significantly (p < 0.05 or 0.01) increased in groups 3 and 4 as compared to group 1.
  • Thyroid weights in group 3, and serum thyroid stimulating hormone level and proliferative activity of follicular cells in groups 2 and 3 were significantly (p < 0.05 or 0.01) elevated.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. 4-AMINOBENZOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843508.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 0 / Thyroid Hormones; 53609-64-6 / diisopropanolnitrosamine; TL2TJE8QTX / 4-Aminobenzoic Acid
  •  go-up   go-down


82. Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, Wenig BM: Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol; 2008 Nov;130(5):736-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma.
  • Distinguishing follicular variant of papillary carcinoma (FVPC) from follicular adenoma and follicular carcinoma can be difficult if nuclear features of papillary carcinoma are not well developed or only focally present.
  • [MeSH-major] Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenoma / diagnosis. Adenoma / pathology. Adult. Cell Nucleus / pathology. Diagnostic Errors / prevention & control. Female. Humans. Male. Middle Aged. Observer Variation. Pathology, Surgical / standards

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2008 Nov;130(5):683-6 [18854259.001]
  • (PMID = 18854266.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Pujani M, Arora B, Pujani M, Singh SK, Tejwani N: Role of Ki-67 as a proliferative marker in lesions of thyroid. Indian J Cancer; 2010 Jul-Sep;47(3):304-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Specific criteria are used to diagnose thyroid neoplasms; however, the distinction between certain neoplasms, such as follicular adenoma and carcinoma, could be difficult.
  • AIMS: To evaluate the role of the proliferative marker Ki-67 in nonneoplastic and neoplastic lesions of the thyroid, with a special emphasis on the distinction between follicular adenoma and follicular carcinoma.
  • A statistically significant difference was observed in Ki-67 counts between multinodular goiter vs papillary carcinoma (P < 0.05) and follicular adenoma vs follicular carcinoma (P < 0.05).
  • CONCLUSIONS: In the present study, Ki-67 was found to be useful in differentiating between follicular adenoma and follicular carcinoma, but since the sample size of our study was small, larger studies are needed to confirm this observation as well as to assign a cutoff value for differentiating benign from malignant tumors.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / metabolism. Carcinoma / diagnosis. Goiter, Nodular / diagnosis. Ki-67 Antigen / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Cancer. 2011 Jul-Sep;48(3):378 [21921351.001]
  • (PMID = 20587907.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


84. Mitselou A, Ioachim E, Peschos D, Charalabopoulos K, Michael M, Agnantis NJ, Vougiouklakis T: E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol; 2007 Mar;29(1):54-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 55 TG carcinomas, 40 TG adenomas, 40 cases of hyperplastic TG disorders and 20 cases of normal TG autopsy samples, were evaluated by immunohistochemistry.
  • RESULTS: Immunostaining of syndecan-1 and E-cadherin was strong in normal follicular TG epithelial cells, and located mainly in basolateral membrane.
  • No significant change was seen in either molecule in hyperplastic TG disorders compared with TG adenomas.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Cadherins / metabolism. Carcinoma, Papillary / metabolism. Syndecan-1 / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Differentiation. Humans. Middle Aged. Thyroid Gland / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431390.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / SDC1 protein, human; 0 / Syndecan-1
  •  go-up   go-down


85. Went PT, Sauter G, Oberholzer M, Bubendorf L: Abundant expression of AMACR in many distinct tumour types. Pathology; 2006 Oct;38(5):426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AMACR expression was equally frequent in colorectal adenomas and carcinomas.
  • In the thyroid, AMACR expression was found in 42% of the follicular carcinomas but in only 16% of follicular adenomas.
  • However, a more detailed analysis on a thyroid tissue microarray did not confirm a significant difference of AMACR expression in follicular adenoma and carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008281.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


86. de la Torre NG, Buley I, Wass JA, Turner HE: Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer; 2006 Sep;13(3):931-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using immunohistochemistry for CD34, lymphatic vessel endothelial receptor-1 (LYVE-1) (specific markers for vascular and lymphatic endothelium respectively), vascular endothelial growth factor (VEGF-A), VEGF-C and fibroblast growth factor-2 (FGF-2), this study analyses microvascular density (MVD), lymphatic vascular density (LVD), and expression of angiogenic and lymphangiogenic factors in normal thyroid (NT; n=19), multinodular goitre (n=25), toxic multinodular goitre (n=8), Graves' hyperplasia (n=22), follicular adenoma (n=54), papillary carcinoma (PC; n=27), incidental papillary microcarcinoma (PMC; n=8), follicular carcinoma (FC; n=20) and medullary carcinoma (MC; n=8).
  • This may be an important mechanism underlying the differences in metastatic behaviour between papillary and follicular thyroid cancer.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954441.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


87. Terris DJ, Gourin CG, Chin E: Minimally invasive thyroidectomy: basic and advanced techniques. Laryngoscope; 2006 Mar;116(3):350-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common diagnosis was follicular or Hürthle cell adenoma (29%), followed by papillary or follicular cancer (26%).
  • The majority of patients had follicular adenoma (42.9%) or papillary carcinoma (21.4%) as their primary diagnosis.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Minimally Invasive Surgical Procedures. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540887.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Bogdańska M, Górnicka B, Ziarkiewicz-Wróblewska B, Koperski L, Morton M, Wasiutyński A: [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms]. Endokrynol Pol; 2006 Jul-Aug;57(4):314-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
  • INTRODUCTION: Estimation of malignancy in thyroid follicular neoplasms is a common diagnostic problem, thus revealing of differences in expression of some antigens in both benign and malignant lesions seems to be essential.
  • The aim of this study is to evaluate the immunohistochemical expression of CD15, galectin-3 and HBME-1 in follicular adenomas and carcinomas.
  • MATERIAL AND METHODS: Samples of 38 follicular adenomas (23 "classical", 5 with intracapsular invasion, 10 oncocytic) and 15 follicular carcinomas (9 "classic", 6 oncocytic) were stained immunohistochemically with anti-CD15, galectin-3 and HBME-1.
  • RESULTS: In the whole group we found statistically significant differences in CD15 expression between follicular adenomas and carcinomas.
  • "Classic" follicular carcinomas (without oncocytic tumors) showed stronger CD15 and HBME- 1 expression than "classic" adenomas.
  • Adenomas with intracapsular invasion differed from "classic" adenomas only in HBME-1 expression.
  • In the group of nonoxyphilic tumors positive reaction with HBME-1 was more common in adenomas with intracapsular invasion and carcinomas, but positive reaction with anti-CD15--only in carcinomas.
  • [MeSH-major] Adenoma / chemistry. Antigens, CD15 / analysis. Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / chemistry. Galectin 3 / analysis. Thyroid Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006830.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen
  •  go-up   go-down


89. Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, Havelka M: Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors. Endocr Pathol; 2006;17(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TPO expression was investigated using newly available mAb 47 and staining of less than 80% of the follicular cells/specimen as the threshold indicating a malignant lesion.
  • In addition, the variability in the degree of TPO expression found within and between follicular carcinomas, and the significant number of benign adenomas having similar immunostaining patterns, assured us that TPO immunostaining is not sufficiently discriminatory in the differential diagnosis of thyroid cancer versus benign lesions.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Iodide Peroxidase / metabolism. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cesk Patol. 2004 Jan;40(1):18-21 [15035056.001]
  • [Cites] Endocr Pathol. 1998 Winter;9(1):333-338 [12114781.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):875-80 [11556840.001]
  • [Cites] J Pathol. 1996 May;179(1):89-94 [8691351.001]
  • [Cites] Cancer Detect Prev. 1996;20(4):285-93 [8818388.001]
  • [Cites] Endocr J. 1996 Feb;43(1):53-60 [8732452.001]
  • [Cites] Pathol Res Pract. 1997;193(10):705-12 [9505263.001]
  • [Cites] J Clin Endocrinol Metab. 1978 May;46(5):791-9 [262767.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 14;174(3):1148-53 [1996981.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3793-800 [12454013.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):529-34 [7725740.001]
  • [Cites] Eur J Endocrinol. 1994 Nov;131(5):474-9 [7952158.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2478-82 [7852309.001]
  • [Cites] Surgery. 1994 Dec;116(6):1031-5 [7985083.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):871-5 [12820316.001]
  • [Cites] Endocr Pathol. 1999 Autumn;10(3):223-228 [12114702.001]
  • [Cites] Acta Pathol Jpn. 1987 Mar;37(3):425-30 [3618217.001]
  • [Cites] Endocrinol Jpn. 1981 Aug;28(4):381-9 [6305643.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1329-34 [8067701.001]
  • [Cites] Am J Surg. 1990 Sep;160(3):271-6 [2393055.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3036-41 [1710535.001]
  • [Cites] Exp Clin Endocrinol. 1992;100(1-2):51-6 [1281780.001]
  • [Cites] Biochemistry. 2001 Feb 27;40(8):2572-9 [11327880.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Aug;53(2):161-9 [10931096.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 28;1689(2):134-41 [15196594.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Nov;45(5):1089-96 [925133.001]
  • [Cites] Surgery. 1999 Dec;126(6):1200-4 [10598208.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):867-71 [8157713.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17 ):4744-9 [8062273.001]
  • [Cites] Arch Biochem Biophys. 1996 Jun 1;330(1):24-32 [8651700.001]
  • [Cites] Thyroid. 1998 Sep;8(9):745-9 [9777743.001]
  • [Cites] Thyroid. 2000 Feb;10(2):109-15 [10718546.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4977-83 [14557483.001]
  • (PMID = 16760580.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


90. Rivera M, Ricarte-Filho J, Patel S, Tuttle M, Shaha A, Shah JP, Fagin JA, Ghossein RA: Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Hum Pathol; 2010 Feb;41(2):172-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study.
  • Encapsulated thyroid tumors of follicular cell origin with high-grade features (EFHG) are unusual neoplasms.
  • In current classification schemes, they are called atypical adenomas or follicular, papillary, or poorly differentiated carcinoma.
  • All cases of EFHG were defined as encapsulated tumors of follicular cell origin with at least 5 mitoses per 10 high-power fields and/or tumor necrosis.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology


91. Wheeler YY, Stoll LM, Sheth S, Li QK: Metastatic signet ring cell carcinoma presenting as a thyroid nodule: report of a case with fine-needle aspiration cytology. Diagn Cytopathol; 2010 Aug;38(8):597-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, when present they may produce a diagnostic dilemma, particularly when they share some morphologic similarities with primary thyroid lesions and when occurring in patients with occult malignant history.
  • These cytological features may be seen in cases of papillary thyroid carcinoma or signet ring cell follicular adenoma; however, the presence of the signet ring cells is unusual in primary thyroid lesions and raises the possibility of a metastatic lesion to the thyroid.

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 20014306.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Ota Y, Imai T, Onose J, Takami S, Cho YM, Hirose M, Nishikawa A: A 55-week chronic toxicity study of dietary administered kojic acid (KA) in male F344 rats. J Toxicol Sci; 2009 Jun;34(3):305-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the thyroids, diffuse follicular cell hyperplasia at 0.5 and 2.0% and focal follicular cell hyperplasia and follicular adenoma at 2.0% were increased.
  • A thyroid follicular carcinoma was also observed at 2.0%.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. KOJIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483384.001).
  • [ISSN] 1880-3989
  • [Journal-full-title] The Journal of toxicological sciences
  • [ISO-abbreviation] J Toxicol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Food Additives; 0 / Pyrones; 6K23F1TT52 / kojic acid; EC 2.3.2.2 / gamma-Glutamyltransferase
  •  go-up   go-down


93. Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A: Expression of S100A2 and S100A6 in thyroid carcinomas. Histopathology; 2005 May;46(5):569-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S100A2 was not expressed in normal follicles or follicular tumours, with one exception.
  • In normal follicles, S100A6 expression was always low, while 8.3% of follicular adenomas and 39.5% of follicular carcinomas showed increased expression.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842639.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Chemotactic Factors; 0 / S100 Proteins; 0 / S100A2 protein, human; 105504-00-5 / S100A6 protein, human
  •  go-up   go-down


94. Omidfar K, Moinfar Z, Sohi AN, Tavangar SM, Haghpanah V, Heshmat R, Kashanian S, Larijani B: Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Invest; 2009;38(2):165-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGFRvIII was evaluated on paraffin-embedded tissue specimens of 40 samples of follicular carcinomas, papillary carcinomas, medullary carcinomas, follicular adenomas, and goiter of the thyroid gland by immunohistochemistry.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330625.001).
  • [ISSN] 1532-4311
  • [Journal-full-title] Immunological investigations
  • [ISO-abbreviation] Immunol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


95. Hamada N, Noh JY, Okamoto Y, Ueda M, Konishi T, Fujisawa T, Ito K, Ito K: Measuring thyroglobulin autoantibodies by sensitive assay is important for assessing the presence of thyroid autoimmunity in areas with high iodine intake. Endocr J; 2010;57(7):645-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 146 patients with a pathological diagnosis of follicular adenoma were selected as subjects.

  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467162.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 9010-34-8 / Thyroglobulin; 9679TC07X4 / Iodine
  •  go-up   go-down


96. Jabiev AA, Ikeda MH, Reis IM, Solorzano CC, Lew JI: Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules. Ann Surg Oncol; 2009 Nov;16(11):3140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 115 operated patients with solitary thyroid nodules, 53% (61/115) had DTC [papillary, 59%; follicular variant/papillary, 34%; Hürthle cell, 5%; and follicular, 2%] and 47% (54/115) had BD [hyperplastic, 56%; follicular adenoma, 31%; lymphocytic thyroiditis, 7%; and Hürthle cell adenoma, 6%].
  • [MeSH-major] Carcinoma, Papillary, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / ultrasonography

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S301 [20839063.001]
  • [CommentIn] Ann Surg Oncol. 2011 Jan;18(1):292 [20490696.001]
  • (PMID = 19655201.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Verhulst P, Devos P, Aubert S, Buob D, Cranshaw I, Do Cao C, Pattou F, Carnaille B, Wemeau JL, Leteurtre E: A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid. Virchows Arch; 2008 Mar;452(3):233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologic examination is the gold standard for diagnosing papillary thyroid carcinoma (PTC).
  • This diagnosis, especially for the follicular variant, may be variable even among experts.
  • Our objective was to analyze the frequency of PTC microscopic criteria in a series of thyroid tumors including follicular adenoma (FA) and PTC to build a score which could constitute a novel way for microscopic analysis of such thyroid tumors.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):16-8 [11791591.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):213-23 [17308358.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):19-21 [11789725.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Jul;5(4):573-84 [16013975.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):225-34 [17308359.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):936-41 [16946010.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):244-50 [16798933.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):350-5 [14758551.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):799-804 [17060774.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):131-4 [12165661.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):984-8 [16831055.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):824-30 [16784981.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1081-2 [14652806.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):249-60 [17252232.001]
  • [Cites] World J Surg. 2006 May;30(5):752-8 [16680590.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Am J Clin Pathol. 2002 Oct;118(4):602-3; author reply 605-6 [12375648.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1508-14 [12409728.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Surgery. 2005 Dec;138(6):1050-6; discussion 1056-7 [16360390.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Ann Pathol. 2003 Feb;23(1):7-10 [12743495.001]
  • (PMID = 18239937.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Harsh M, Dimri P, Nagarkar NM: Osseous metaplasia and mature bone formation with extramedullary hematopoiesis in follicular adenoma of thyroid gland. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):377-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osseous metaplasia and mature bone formation with extramedullary hematopoiesis in follicular adenoma of thyroid gland.
  • Follicular adenomas of the thyroid may be subjected to degenerative changes like hemorrhagic and cystic changes, fibrosis, and calcification.
  • We describe a case of follicular adenoma with histologically proven osseous metaplasia and mature bone formation with EMH in a middle- aged woman, which, to our knowledge, is the first case in English language literature.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Hematopoiesis, Extramedullary. Ossification, Heterotopic. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679966.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


99. Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A: Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene; 2010 Oct 21;29(42):5678-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
  • In this study, we show that 52% of the Pten(-/-) female mice, but only 12% of the males, develop follicular adenomas by 1 year of age.
  • In addition, 50% of female mutants, but only 35% of males older than 1 year of age develop invasive, and often metastatic, follicular carcinomas.
  • Furthermore, while genetic ablation of one Cdkn1b allele accelerated the development of neoplastic lesions, it also abolished the gender differences in survival and reduced the difference in neoplastic lesion development rate, underlining a key role of p27 in mediating estrogen action in the thyroid follicular cells.
  • These data, based on a clinically relevant model of thyroid follicular carcinoma, provide, to the best of our knowledge, for the first time in vivo evidence that circulating estrogens are directly responsible for the increased female susceptibility to thyroid disease, at least on activation of the PI3K pathway, and provide new insights into the gender-based differences characterizing thyroid neoplastic disorders.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 1999 Dec;9(12):1265-71 [10646670.001]
  • [Cites] Int J Oncol. 2010 May;36(5):1067-80 [20372779.001]
  • [Cites] Thyroid. 2001 Nov;11(11):1017-23 [11762710.001]
  • [Cites] Thyroid. 2002 Nov;12(11):963-9 [12490073.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41355-66 [12904306.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):375-8 [8536638.001]
  • [Cites] Cell. 1996 May 31;85(5):721-32 [8646780.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4238-45 [15899815.001]
  • [Cites] Cancer J. 2005 Mar-Apr;11(2):104-5 [15969983.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5467-74 [16785999.001]
  • [Cites] Mol Pharmacol. 2006 Oct;70(4):1414-23 [16835357.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):11-7 [17133106.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):959-66 [17283127.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90 [17426084.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):444-9 [18199538.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Aug;8(5):367-77 [18690843.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4141-5 [18628528.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2440-7 [18831514.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3689-94 [19351816.001]
  • [Cites] Thyroid. 2010 Jan;20(1):33-41 [20067378.001]
  • [Cites] Endocrinology. 2010 Apr;151(4):1929-39 [20133453.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1072-7 [11238488.001]
  • (PMID = 20676139.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK015070; United States / NCI NIH HHS / CA / R01 CA097097-06; United States / NIDDK NIH HHS / DK / R37 DK015070; United States / NIDDK NIH HHS / DK / DK15070; United States / NCI NIH HHS / CA / R01 CA128943; United States / NCI NIH HHS / CA / R01 CA128943-02; United States / NCI NIH HHS / CA / CA97097; United States / NIDDK NIH HHS / DK / DK015070-38; United States / NCI NIH HHS / CA / CA128943; United States / NCI NIH HHS / CA / CA097097-06; United States / NIDDK NIH HHS / DK / R37 DK015070-38; United States / NCI NIH HHS / CA / CA128943-02; United States / NIDDK NIH HHS / DK / DK20595; United States / NIDDK NIH HHS / DK / P30 DK020595; United States / NCI NIH HHS / CA / R01 CA097097; United States / NIDDK NIH HHS / DK / P60 DK020595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS217275; NLM/ PMC2967724
  •  go-up   go-down


100. Lado Abeal J, Domínguez Gerpe L: Genetic bases of benign thyroid processes. Endocrinol Nutr; 2008 Mar;55(3):132-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The genetic bases of toxic adenomas and toxic multinodular goiters have been determined and several genes involved in the development of follicular thyroid adenomas have been identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Sociedad Española de Endocrinología y Nutrición. Published by Elsevier Espana. All rights reserved.
  • (PMID = 22967879.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down






Advertisement